Surrogate End Points in Clinical Trials: Are We Being Misled?

Annals of Internal Medicine

Volumn 125, Issue 7, 1996, Pages 605-613

  Fleming, Thomas R ^b   DeMets, David L ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN; METHODOLOGY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; REVIEW; STANDARD;

CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; HUMANS;

EID: 0030268577     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-125-7-199610010-00011     Document Type: Article

References (79)

1. Fleming TR. Evaluating therapeutic interventions: some issues and experiences (with discussion and rejoinder). Statistical Science. 1992;7:428-56.
2. Fleming TR. Evaluation of active control trials in AIDS. J Acquir Immune Defic Syndr. 1990;3(Suppl 2)S82-7.
3. Johnson JR, Temple R. Food and Drug Administration requirements for approval of new anticancer drugs. Cancer Treat Rep. 1985;69:1155-9.
4. Ellenberg SS, Hamilton JM. Surrogate endpoints in clinical trials: cancer. Stat Med. 1989;8:405-13.
5. Fleming TR, Prentice RL, Pepe MS, Glidden D. Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research. Stat Med. 1994;13:955-68.
6. Herson J. The use of surrogate endpoints in clinical trials. Stat Med. 1989; 8:403-4.
7. Hillis A, Seigel D. Surrogate endpoints in clinical trials: ophthalmologic disorders. Stat Med. 1989;8:427-30.
8. Kosorok MR, Fleming TR. Using surrogate failure time data to increase cost effectiveness in clinical trials. Biometrika. 1993;80:823-33.
9. Machado SC, Gail MH, Ellenberg SS. On the use of laboratory markers as surrogates for clinical endpoints in the evaluation of treatment for HIV infection. J Acquir Immune Defic Syndr. 1990;3:1065-73.
10. Pepe MS, Reilly M, Fleming TR. Auxiliary outcome data and the mean score method. Journal of Statistical Planning and Inference. 1994;42:137-60.
11. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med. 1989;8:431-40.
12. Wittes J, Lakatos E, Probstfield J. Surrogate endpoints in clinical triais: cardiovascular diseases. Stat Med 1989;8:415-25.
13. Temple RJ. A regulatory authority's opinion about surrogate endpoints. In: Nimmo WS, Tucker GT, eds. Clinical Measurement in Drug Evaluation New York: J Wiley; 1995.
14. Ellenberg SS. Surrogate end points in clinical trials [Editorial]. BMJ. 1991; 302:63-4
15. Fleming TR. Surrogate markers in AIDS and cancer trials. Stat Med. 1994; 13:1423-35.
16. Lagakos SW, Hoth DF. Surrogate markers in AIDS: where are we? Ann Intern Med. 1992;116:599-601.
17. Lin DY, Fischl MA, Schoenfeld DA. Evaluating the role of CD4-lymphocyte counts as surrogate endpoints in human immunodeficiency virus clinical trials. Stat Med. 1993;12:835-42.
18. Aboulker JP, Swart AM: Preliminary analysis of the Concorde Trial. Concorde Coordinating Committee [Letter]. Lancet. 1993;341:889-90.
19. + lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine. Ann Intern Med. 1993;118: 674-80.
20. De Gruttola V, Wulfsohn M, Fischl M, Tsiatis A. Modeling the relationship between survival and CD4 lymphocytes in patients with AIDS and AIDS-related complex. J Acquir Immune Defic Syndr. 1993;6:359-65.
21. Jacobson MA, Bacchetti P, Kolokathis A, Chaisson RE, Szabo S, Polsky B, et al. Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine. BMJ. 1991;302:73-8.
22. Nowak R. In Concorde's wake: is the AIDS clinical-trials program flawed? Journal of NIH Research. 1993;5:37-9.
23. Volberding PA, Lagakos SW, Grimes J, Stein DS, Balfour HH, Reichman RC, et al. The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group. JAMA. 1994;272:437-42.
24. Volberding PA, Lagakos SW, Koch MA, Pettinelli C, Myers MW, Booth DK, et al. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. N Engl J Med. 1990;322:941-9.
25. Boissel JP, Collet JP, Moleur P, Haugh M. Surrogate endpoints: a basis for a rationale approach. Eur J Clin Pharmacol. 1992;43:235-44.
26. Preliminary Report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med. 1989; 321:406-12.
27. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991; 324:781-8.
28. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhythmia Suppression Trial II Investigators. N Engl J Med. 1992;327:227-33.
29. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation. 1990;82:1106-16.
30. Hine LK, Laird N, Hewitt P, Chalmers TC. Meta-analytic evidence against prophylactic use of lidocaine in acute myocardial infarction. Arch Intern Med. 1989;149:2694-8.
31. MacMahon S, Collins R, Peto R, Koster RW, Yusuf S. Effects of prophylactic lidocaine in suspected acute myocardial infarction. An overview of results from the randomized, controlled trials. JAMA. 1988;260:1910-6.
32. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med. 1987;316:1429-35.
33. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captropril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. The SAVE Investigators. N Engl J Med. 1992; 327:669-77.
34. Effects of enalaprif on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med. 1987;316:1429-35.
35. Feldman AM, Bristow MR, Parmley WW, Carson PE, Pepine CJ, Gilbert EM, et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group. N Engl J Med. 1993;329:149-55.
36. Rationale, design, implementation, and baseline characteristics of patients in the DIG trial: a large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure. The Digitalis Investigation Group. Control Clin Trials. 1996;17:77-97.
37. Packer M, Carver JR, Rodehoffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med. 1991;325:1468-75.
38. Packer M, Rouleau J, Swedberg K, Pitt B, Fisher L, Klepper M, et al. Effect of Flosequinan on survival in chronic heart failure: preliminary results of the PROFILE study [Abstract]. Circulation. 1993;88(Suppl I):I-301.
39. Law MR, Thompson SG, Wald NJ. Assessing possible hazards of reducing serum cholesterol. BMJ. 1994;308:373-9.
40. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischemic heart disease? BMJ. 1994;308:367-72.
41. Rossouw JE, Lewis B, Rifkind BM. The value of lowering cholesterol after myocardial infarction N Engl J Med. 1990;323:1112-9.
42. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360-81.
43. Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ. 1990;301:309-14.
44. Holme I. Relation of coronary heart disease incidence and total mortality to plasma cholesterol reduction in randomised trials: use of meta-analysis. Br Heart J 1993;69(1 Suppl):S42-7.
45. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ. 1994;308:367-72.
46. Law MR, Thompson SG, Wald NJ. Assessing possible hazards of reducing serum cholesterol. BMJ. 1994;308:373-9.
47. Gordon DJ. Cholesterol lowering and total mortality. In Rifkind BM, ed. Contemporary Issues in Cholesterol Lowering: Clinical and Population Aspects. New York: Marcel Dekker; 1994.
48. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994;344: 1383-9.
49. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context Lancet. 1990;335:827-38.
50. Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group. JAMA. 1979;242:2562-71.
51. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991;265: 3255-64.
52. Furberg CD, Berglund G, Manolio TA, Psaty BM. Overtreatment and undertreatment of hypertension. J Intern Med. 1994;235:387-97.
53. Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Lemaitre R, Smith NL, et al. The risk of incident myocardial infarction associated with anti-hypertensive drug therapies [Abstract]. Circulation. 1996;91:925.
54. Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. BMJ. 1989;299:1187-92.
55. Moertel CG. Improving the efficiency of clinical trials: a medical perspective. Stat Med. 1984;3:455-68.
56. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol. 1992;10:896-903.
57. Sande MA, Carpenter CC, Cobbs CG, Holmes KK, Sanford JD. Anti-retroviral therapy for adult HIV-infected patients. Recommendations from a state-of-the-art conference. National Institute of Allergy and Infectious Diseases State-of-the-Art Panel on Anti-Retroviral Therapy for Adult HIV-Infected Patients. JAMA. 1993;270:2583-9.
58. Riggs BL, Hodgson SF, O'Fallon WM, Chao EY, Wahner HW, Muhs JM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med. 1990;322:802-9.
59. Riggs BL, Seeman E, Hodgson SF, Taves DR, O'Fallon WM. Effect of the fluoride/calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis. Comparison with conventional therapy. N Engl J Med. 1982; 306:446-50.
60. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. The International Chronic Granulomatous Disease Cooperative Study Group. N Engl J Med. 1991;324:509-16.
61. Comstock GW. Identification of an effective vaccine against tuberculosis. Am Rev Respir Dis. 1988;138:479-80.
62. Urokinase-Streptokinase embolism trial. Phase 2 results. A cooperative study. JAMA. 1974;229:1606-13.
63. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI Study Group. N Engl J Med. 1985;312:932-6.
64. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio Della Streptochinasi nell'Infarto Miocardico (GISSI). Lancet. 1986;1:397-402.
65. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet. 1988;2: 349-60.
66. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Soprawivenza nell'Infarto Miocardico. Lancet. 1990;336:65-71.
67. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. The International Study Group. Lancet. 1990;336: 71-5.
68. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO Investigators. N Engl J Med. 1993; 329:673-82.
69. Fontana RS, Sanderson DR, Taylor WF, Woolner LB, Miller WE, Muhm JR, et al. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Mayo Clinic Study. Am Rev Respir Dis. 1984;130:561-5.
70. Fontana RS, Sanderson DR, Woolner LB, Taylor WF, Miller WE, Muhm JR. Lung cancer screening: the Mayo program. J Occup Med. 1986;28:746-50.
71. Berson EL, Rosner B, Sandberg MA, Hayes KC, Nicholson BW, Weigel-DiFranco C, et al. A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa. Arch Ophthalmol. 1993;111:761-72.
72. Massof RW, Finkelstein D. Supplemental vitamin A retards loss of ERG amplitude in retinitis pigmentosa [Editorial]. Arch Ophthalmol. 1993;111: 751-4.
73. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med. 1980;93:391-8.
74. Hujoel PP, DeRouen TA. A survey of endpoint characteristics in periodontal clinical trials published 1988-1992, and implications for future studies. J Clin Periodontol. 1995;22:397-407.
75. Hujoel PP, DeRouen TA, Leroux B, Powell LV, Kiyak HA. The validity of probing attachment levels as a surrogate for tooth loss in the elderly [Abstract]. J Dent Res. 1996;75:370.
76. Coronary artery surgery study (CASS): a randomized trial of coronary artery bypass surgery. Survival data. Circulation. 1983;68:939-50.
77. Lin DV, Fleming TR, DeGruttola V. Estimating the proportion of treatment effect explained by a surrogate marker. Stat Med. 1996; [In press].
78. Freedman LS, Graubard BL, Schatzkin A. Statistical validation of intermediate endpoints for chronic diseases. Stat Med. 1992;11:167-78.
79. DeGruttola V, Fleming T, Lin DY, Coombs R. Validating surrogate markers - are we being naive? J Infect Dis. [In press].